(NYSE: DNA) Ginkgo Bioworks Holdings's forecast annual revenue growth rate of 29.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.69%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.2%.
Ginkgo Bioworks Holdings's revenue in 2023 is $527,915,000.On average, 3 Wall Street analysts forecast DNA's revenue for 2023 to be $769,136,057,157, with the lowest DNA revenue forecast at $632,433,435,990, and the highest DNA revenue forecast at $989,389,731,150. On average, 2 Wall Street analysts forecast DNA's revenue for 2024 to be $1,390,771,565,219, with the lowest DNA revenue forecast at $1,281,938,694,792, and the highest DNA revenue forecast at $1,499,604,435,645.
In 2025, DNA is forecast to generate $2,287,139,261,842 in revenue, with the lowest revenue forecast at $2,275,596,381,645 and the highest revenue forecast at $2,298,682,142,039.